Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 17/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634095 | 1.00 | CCR4 (0.60) | CCR4PKMLMNAMAPTGAA | |
| SCHEMBL21048010 | 0.80 | CCR4 (0.60) | CCR4PKMLMNAMAPTGAA | |
| SCHEMBL1731947 | 0.77 | CCR4 (0.67) | CCR4 | |
| SCHEMBL1731810 | 0.77 | CCR4 (0.82) | CCR4 | |
| SCHEMBL1731821 | 0.77 | CCR4 (0.82) | CCR4 | |
| SCHEMBL1731223 | 0.76 | CCR4 (0.82) | CCR4 | |
| SCHEMBL22086595 | 0.76 | CCR4 (0.50) | CCR4PKMLMNAGAA | |
| SCHEMBL21047961 | 0.75 | CCR4 (0.64) | CCR4LMNAGAA | |
| SCHEMBL30634098 | 0.75 | CCR4 (0.64) | CCR4LMNAGAA | |
| SCHEMBL16111175 | 0.75 | PKM (0.57) | CCR4PKMLMNAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3707126-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-12-26 | — | — | US | disclosed |
| US-12071424-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2024-08-27 | — | — | US | disclosed |
| CN-111566089-B | IRE1 small molecule inhibitors | 康奈尔大学 | 2023-11-17 | — | — | CN | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11634403-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| CN-111566089-A | IRE1 small molecule inhibitor | 康奈尔大学 | 2020-08-21 | — | — | CN | disclosed |
| US-10745379-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2020-08-18 | — | — | US | disclosed |
| US-10745379-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200157079-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157079-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| EP-3630748-A1 | IRE1 SMALL MOLECULE INHIBITORS | Quentis Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20190169160-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| US-20190169160-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| WO-2018222918-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| US-20180346446-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CCR4 3191/4885PKM 2987/4885LMNA 2127/4885 |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CCR4 3191/4885PKM 2987/4885LMNA 2127/4885 |
| US-20200157079-A1 | IRE1 Small Molecule Inhibitors | XBP1, ERN2, ERN1 | CCR4 3191/4885PKM 2987/4885LMNA 2127/4885 |
| US-11634403-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CCR4 3191/4885PKM 2987/4885LMNA 2127/4885 |
| US-12071424-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CCR4 3191/4885PKM 2987/4885LMNA 2127/4885 |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | XBP1, DDIT3, HSP90B1 | CCR4 1290/4885PKM 3719/4885LMNA 1598/4885 |
| US-11649224-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CCR4 3191/4885PKM 2987/4885LMNA 2127/4885 |
| US-20180346446-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CCR4 3191/4885PKM 2987/4885LMNA 2127/4885 |
| US-20190169160-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CCR4 3191/4885PKM 2987/4885LMNA 2127/4885 |
| US-10745379-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CCR4 3191/4885PKM 2987/4885LMNA 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.